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Exposure to ionising radiation is an established risk factor for many cancers. We conducted a case–control study to investigate
whether exposure to low dose ionisation radiation from diagnostic x-ray procedures could be established as a risk factor for prostate
cancer. In all 431 young-onset prostate cancer cases and 409 controls frequency matched by age were included. Exposures to barium
meal, barium enema, hip x-rays, leg x-rays and intravenous pyelogram (IVP) were considered. Exposures to barium enema (adjusted
odds ratio (OR) 2.06, 95% confidence interval (CI) 1.01–4.20) and hip x-rays (adjusted OR 2.23, 95% CI 1.42–3.49) at least 5 years
before diagnosis were significantly associated with increased prostate cancer. For those with a family history of cancer, exposures to
hip x-rays dating 10 or 20 years before diagnosis were associated with a significantly increased risk of prostate cancer: adjusted OR
5.01, 95% CI 1.64–15.31 and adjusted OR 14.23, 95% CI 1.83–110.74, respectively. Our findings show that exposure of the prostate
gland to diagnostic radiological procedures may be associated with increased cancer risk. This effect seems to be modified by a
positive family history of cancer suggesting that genetic factors may play a role in this risk association.
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Prostate cancer (PC) is the most common late-onset cancer in
males in developed Western countries (Selley et al, 1997).
Compared with other common cancers like breast cancer, the
aetiology of prostate cancer is not well understood (Gronberg,
2003). Studies in the past have looked at the association between
occupational exposure to radiation and an increased risk of
prostate cancer and provided conflicting evidence (Beral et al,
1985; Atkinson et al, 2004). It is interesting, however, that in our
literature review we found no published papers on the possible link
between exposures to diagnostic radiological procedures and
increased prostate cancer risk.
We therefore investigated if there is any association between
exposure to low dose ionisation radiation from diagnostic
radiological procedures and an increased risk of prostate cancer.
Our study focussed on young men with prostate cancer (young
onset PC or YOPC) in whom genetic susceptibility may play a role
in the incidence and progression of the disease. We conducted a
case–control analysis of exposure to five common radiological
procedures: barium meal, barium enema, intra-venous pyelogram
(IVP), upper leg x-rays and hip/pelvic x-rays, each of which would
deliver radiation dose in the region of the prostate. We looked at
exposures dating at least 5 years, 10 years and 20 years before the
diagnosis of prostate cancer to exclude bias from exposures related
to diagnostic and therapeutic procedures for the disease.
METHODS
Study participants and data collection
Our study population comprised 431 cases and 409 frequency
matched controls from the United Kingdom (UK). Recruitment of
cases (to The UK Genetic Prostate Cancer Study; UKGPCS) was
through notification by consultants and selected referral centres to
the Institute of Cancer Research and The Royal Marsden NHS
Foundation Trust. Cases were 60 years or younger and lived in the
UK. For each case, controls were recruited from general practice
surgeries where the case was registered. Controls were frequency
matched to cases by age within 5 years on either side.
Subjects were sent a postal questionnaire including questions on
demographic characteristics, lifestyle, occupational exposures and
history of diagnostic radiology procedures. The study was
approved by the multiregional ethics committee and loco-regional
ethical approval was sought where necessary. For this case–
control analysis we used data collected on history of barium meal,
barium enema, IVP, upper leg x-rays and hip/pelvic x-rays.
Data analysis
An unconditional logistic regression was performed in SPSS
version 11.5. Unadjusted odds ratios (OR) and 95 percent
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exposure variables. Adjustment was done for age at diagnosis of
prostate cancer (Gronberg, 2003) and social class based on
occupation. We did not adjust for smoking as there is little
evidence to suggest it is a confounder for prostate cancer and this
was further confirmed in our own analyses. P-values were
calculated using the w
2 test for categorical exposure variables.
Approximately five percent of the data had missing values and
have been excluded from the analysis.
Since some radiological procedures are more common than
others such as hip and leg x-ray as compared to barium enema, the
study power was calculated based on the exposure rates in controls
ranging from 5 to 20 percent. In all 800 subjects (400 cases and 400
controls) would provide 80 percent study power to detect risks
(significant at the 5 percent level) of 2.2, 1.8 and 1.6 when exposure
rate in controls is 5, 10 and 20 percent respectively. Similarly, the
study was powered at 80 percent to detect protective risks of 0.2,
0.3 and 0.4 with exposure rates of 5, 10 and 20 percent respectively
in controls(Dupont and Plummer, 1990).
Our original dataset did not have information on dates of
exposure for all the radiological procedures undergone by subjects.
Subjects instead had been asked for age at first exposure to various
radiological procedures. We chose therefore to restrict further
analyses to those subjects who had only one procedure and
considered exposures at the following time periods: at least 5, 10
and 20 years before diagnosis. A separate analysis was also done
for those with a family history of any cancer, which was defined as
cancer in any first or second degree relative at any age.
The aetiologic fraction was also calculated using the Meittinen
formula (Meittinen, 1974) both with and without controlling for a
family history of cancer. We also estimated typical doses provided
to the prostate gland from diagnostic x-ray examinations. We used
doses either to the urinary bladder or gonads (female) from
radiological exposures as a proxy for the dose to the prostate (Hart
and Hillier, 1996; Walley and Mantgani, 1997; Ruiz-Cruces and
Ruiz, 2000; Hart and Wall, 2002). In some cases the dose was
estimated from the incident skin dose using EffDose v.1.0 (which
uses data taken from the NRPB report on effective doses from
diagnostic radiation (Hart et al, 1994)).
RESULTS
Baseline demographic characteristics of cases and controls are
presented in Table 1.
All subjects
Table 2 summarises the results of our case–control analysis of all
subjects irrespective of family history of cancer. The univariate
analysis found a significantly increased risk of prostate cancer for
the following diagnostic procedures: barium enema and hip/pelvic
x-rays, when exposures at least 5 years before diagnosis were
considered. Even after adjustment for age and social class, odds
ratios remained significantly increased: barium enema OR 2.06,
95% CI 1.01–4.20 and hip/pelvic x-rays OR 2.23, 95% CI 1.42–
3.49.
When we considered exposure to barium enema occurring at
least 10 years before prostate cancer diagnosis, the association with
increased prostate cancer risk strengthened: adjusted OR 2.49, 95%
CI 1.07–5.78. Similarly, for exposures to hip/pelvic x-rays 10 or
more years before diagnosis, the association remained significant
even after adjustment and became stronger: OR 2.65, 95%
CI 1.60–4.39.
In the case of exposures dating back at least 20 years before
diagnosis, significant results were obtained only for hip/pelvic
x-rays (OR 2.87 95% CI 1.47–5.62). No significant associations
were found between increased prostate cancer risk and exposures
to barium meal, upper leg x-rays or IVP.
Subjects with a family history of cancer
Table 3 summarises the results of the analysis of those subjects
with a family history of cancer. For exposures at least 5 years
before diagnosis of prostate cancer, significantly raised odds ratios
were found in the case of hip/pelvic x-rays, OR 3.46, 95% CI 1.44–
8.34. Even after adjustment the odds ratios were significantly
increased (OR 3.55, 95% CI 1.46–8.58). When exposures dating at
least 10 years and 20 years before diagnosis were considered, only
hip/pelvic x-rays were associated with a significantly increased risk
of prostate cancer. After adjustment for age at diagnosis and social
class, these associations remained significant: OR 5.01, 95% CI
1.64–15.31, and OR 14.23, 95% CI 1.83–110.74, respectively. No
Table 1 Baseline demographic characteristics of cases and controls
Cases
(n¼431)
Controls
(n¼409) OR (95% CI)
Mean age at diagnosis
a
(years)
55.11 54.42 1.05 (1.01–1.08)
Social class based on occupation
I 33 (8.8%) 32 (8.6%) 1.00
II 140 (37.1%) 163 (43.9%) 0.83 (0.49–1.42)
IIINM 41 (10.9%) 38 (10.2%) 1.05 (0.54–2.02)
IIIM 114 (30.2%) 92 (24.8%) 1.20 (0.69–2.10)
IV 31 (8.2%) 28 (7.5%) 1.07 (0.53–2.17)
V 9 (2.4%) 6 (1.6%) 1.46 (0.46–4.56)
CI¼confidence interval; OR¼odds ratio.
aFor controls this corresponds to matched
case patient’s age at first diagnosis of prostate cancer.
Table 2 Case–control analysis: association between exposure to
diagnostic x-rays and prostate cancer
Exposure variable
Number
exposed
(total)
Crude OR
(95% CI)
Adjusted
OR
a (95% CI)
Barium meal
45 years 159 (678) 1.28 (0.90–1.82) 1.21 (0.84–1.73)
410 years 138 (657) 1.25 (0.86–1.83) 1.18 (0.80–1.72)
420 years 90 (609) 1.04 (0.66–1.62) 0.96 (0.61–1.52)
Barium enema
45 years 36 (666) 2.15 (1.05–4.36)
w 2.06 (1.01–4.20)
w
410 years 27 (657) 2.55 (1.10–5.90)
w 2.49 (1.07–5.78)
w
420 years 10 (640) 1.61 (0.45–5.76) 1.49 (0.41–5.37)
IVP (kidneys)
45 years 49 (687) 1.63 (0.90–2.96) 1.67 (0.92–3.03)
410 years 37 (675) 1.51 (0.77–2.97) 1.55 (0.79–3.06)
420 years 19 (657) 1.77 (0.69–4.55) 1.69 (0.66–4.36)
Hip/pelvic x-ray
45 years 97 (583) 2.20 (1.41–3.45)
w 2.23 (1.42–3.49)
z
410 years 78 (564) 2.57 (1.56–4.23)
z 2.65 (1.60–4.39)
z
420 years 42 (528) 2.72 (1.40–5.30)
w 2.87 (1.47–5.62)
w
Upper leg x-ray
45 years 60 (643) 1.12 (0.66–1.90) 1.11 (0.65–1.89)
410 years 48 (631) 1.46 (0.81–2.66) 1.45 (0.80–2.64)
420 years 39 (622) 1.35 (0.70–2.60) 1.37 (0.71–2.65)
OR¼Odds Ratio; CI¼Confidence interval.
wP-value significant;
zP-valueo0.001.
aAdjusted for age at diagnosis and social class.
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the other diagnostic radiology procedures (barium meal, barium
enema, IVP, upper leg x-rays) and prostate cancer risk.
Aetiologic fraction
Table 4 summarises the results for aetiologic fraction.
The aetiologic fraction was the highest for exposures to hip/pelvic
x-rays as compared with other exposures. About 24% percent
of prostate cancer in the study population was attributable to
hip/pelvic x-rays exposures. When family history factor was
controlled for, the aetiologic fraction decreased slightly to 21%
percent.
Table 5 indicates the mean minimum and maximum exposure
values estimated for the various examination types considered
(with the exception of the upper leg examination where the dose to
the prostate was considered to be negligible).
DISCUSSION
The results of our case–control analysis show that exposure to
some diagnostic radiological procedures may be associated with an
increased risk of prostate cancer. We found a significant
association between increased prostate cancer risk and exposure
to a hip/pelvic x-ray irrespective of a family history of cancer.
Those exposed to hip x-rays were about two and a half times more
likely to have prostate cancer as compared to those without a
previous history of hip x-rays (when considering exposures at least
a decade prior to diagnosis). Similarly, those who had a barium
enema (at least 10 years prior to diagnosis) were about two and
half times more likely to have prostate cancer as compared to those
not exposed to barium enemas. The aetiologic fraction calculations
showed that approximately a fifth of prostate cancer cases in our
study population were attributable to past hip/pelvic x-rays. For
the UK the number of cases of YOPC per year is estimated at 3800
so this equates to about 760 cases of YOPC being attributable to
past hip/pelvic x-rays (CRUK, 2007).
Strengths and limitations of the study
Our study is unique in looking at the relationship between
exposure to low dose ionising radiation from diagnostic radiology
procedures and prostate cancer risk at young age of onset.
Moreover, restricting our study to YOPC cases (i.e. below the age
of 60 years) ensures that only aggressive cases of prostate cancer
are considered rather than mere age-associated prostate changes.
There are some potential limitations with our study, which need
discussion. We had incomplete data on dates of all exposures. To
exclude a temporal bias we only included exposure data on
diagnostic procedures, which could be dated in the analysis.
However, we were unable to investigate the effects of cumulative
exposure to radiation from diagnostic procedures in the region of
the prostate on prostate cancer risk.
Another limitation is that we were unable to stratify our analysis
by family history of prostate cancer because of small numbers.
This would have enabled us to assess the possible role of inherited
predisposition to radiation-induced prostate cancer. We, therefore
conducted a stratified analysis by family history of any cancer as a
proxy marker of genetic susceptibility.
We considered the possibility that the radiological procedures
we have studied may have led to the diagnosis of prostate cancer.
However, with the exception of IVP, upper leg x-rays and hip/
pelvic x-rays it is unlikely that other procedures like barium
enema, barium meal, could contribute to the diagnosis of prostate
cancer. It is also unlikely that exposure is related to diagnosis as we
Table 3 Case–control analysis of subjects with a family history of cancer:
association between exposure to diagnostic x-rays and prostate cancer
Procedure
Number exposed
(total)
Unadjusted OR
(95% CI)
Adjusted OR
a
(95% CI)
Barium meal
45 years 83 (373) 1.17 (0.71–1.92) 1.09 (0.66–1.81)
410
years
71 (361) 1.18 (0.70–1.99) 1.08 (0.63–1.86)
420
years
41 (331) 0.94 (0.49–1.81) 0.86 (0.44–1.67)
Barium enema
45 years 22 (386) 1.74 (0.69–4.36) 1.60 (0.63–4.03)
410
years
19 (383) 2.27 (0.80–6.44) 2.12 (0.74–6.04)
420
years
6 (370) 0.81 (0.16–4.07) 0.68 (0.13–3.45)
IVP
45 years 26 (390) 1.48 (0.64–3.41) 1.44 (0.62–3.33)
410
years
18 (382) 1.23 (0.47–3.25) 1.19 (0.45–3.16)
420
years
10 (374) 1.83 (0.47–7.19) 1.62 (0.41–6.42)
Hip/pelvic x-ray
45 years 30 (299) 3.46 (1.44–8.34)
w 3.55 (1.46–8.58)
w
410
years
22 (291) 4.74 (1.56–14.3)
w 5.01 (1.64–15.31)
w
420
years
14 (283) 13.69 (1.77–106.16)
w 14.23 (1.83–110.74)
w
Upper leg x-ray
45 years 24 (360) 0.89 (0.39–2.04) 0.83 (0.36–1.93)
410
years
20 (356) 1.39 (0.54–3.58) 1.32 (0.51–3.43)
420
years
18 (354) 1.50 (0.55–4.09) 1.46 (0.53–4.02)
OR¼Odds Ratio; CI¼Confidence interval.
wP-value significant.
aAdjusted for age at
diagnosis and social class.
Table 4 Aetiologic fractions
Exposure
Aetiologic
fraction
a (%)
Aetiologic
fraction
b (%)
Barium meal 7.8 5.8
Barium enema 10.6 4.4
IVP kidney 6.4 7.0
Hip and pelvic x-ray 23.7 21.3
Upper leg x-ray 4.9 7.8
aNot controlled for confounding.
bControlled for family history.
Table 5 Mean minimum and maximum estimates of the dose to the
prostate gland
Examination
Mean minimum
dose (mGy)
a
Mean maximum
dose (mGy)
a
Barium enema 10.0 25.0
Barium meal 0.2 0.4
IVP 3.0 4.0
HIP/pelvic 2.0 5.0
aFor diagnostic x-rays the absorbed dose in mGy is numerically equal to the
equivalent organ dose in mSv.
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cancer diagnosis.
Finally, as in all case–control studies, the potential problem of
recall bias exists. In our study it is unlikely that cases would have
preferentially recalled some radiological procedures over others.
This is further illustrated by our results in which not all procedures
are significantly associated with prostate cancer. Similarly, cases
would not have any idea of the dose of ionising radiation delivered
to the prostate from different procedures.
Interpretation of results
To our knowledge this is the first study to report the relation-
ship between low dose ionising radiation from diagnostic
procedures and prostate cancer risk. The link between
ionising radiation and cancer is well established in the literature.
Most of the evidence comes from studies of atomic bomb
survivors (Preston et al, 2003a). It has been estimated that
in the UK about 0.6% of the cumulative risk of cancer to age 75
years can be attributable to diagnostic x-rays and this is equivalent
to about 700 cancer cases a year (Berrington de Gonzalez and
Darby, 2004).
Radiation-induced solid tumours can develop after a latency
period of 10–40 years; however, shorter latent periods could be
observed (Cormack et al, 2004). There is some debate about the
lowest dose of ionising radiation that can result in increased
carcinogenic risks. In the case of x-rays, there is good evidence of
an increased cancer risk at acute doses greater than 50mSv and
some evidence that cancer risks increase at doses above 5mSv
(Brenner et al, 2003). For protracted doses, there is reasonable
evidence that a lifetime exposure exceeding 50mSv increases
cancer risks (Brenner et al, 2003; HPS, 2004). Single diagnostic
x-ray procedures deliver full body radiation effective doses in the
range of 0.01–10mSv (Hart and Wall, 2002). While we have
attempted to estimate radiation doses delivered to the prostate
gland in this paper (Table 5) in the absence of data on actual
exposure conditions for the cases, this should be interpreted with
caution. It is possible that the dose to the prostate for any
individual case could have been significantly greater or smaller
than these values.
In our study, while there appears to be a relationship between
the increased incidence of prostate cancer with hip or pelvic
examinations, no such relationship is seen with IVP examinations
even though a similar dose to the prostate has been estimated for
both these examinations. This could be because of the small
number of IVP exposures in our study population, which affected
the statistical power.
When explaining causality in epidemiological studies, biological
plausibility is an important criterion to be considered. Brenner
et al (2003) point out that based on a linear dose–response, non-
threshold model, ‘the risk of radiation induced cancer should
decrease linearly, without a threshold to arbitrarily low doses’
(Brenner et al, 2003). A pooled analysis of eight cohorts supported
the linearity of the radiation dose response for breast cancer,
and suggested a similarity in risks for acute and fractionated
high-dose rate exposures, though with a much smaller effect
from low-dose rate protracted exposures (Preston et al, 2002).
However, as Cormack et al (2004) point out, it is logical to
assume that qualitatively similar biological processes would be
active, at different doses. In addition, The Health Physics Society
states that the possibility that health effects might occur at small
doses of ionising radiation should not be entirely discounted (HPS,
2004).
Further, the possible role of genetic susceptibility to radiation-
induced prostate cancer should be considered. It is well established
that family history of prostate cancer increases an individual’s risk
of developing prostate cancer (Gronberg, 2003). It has been
suggested in cell studies that inherited G2 chromosomal
radiosensitivity in few individuals is a marker for low penetrance
predisposition to common cancers such as breast cancer and
colorectal cancer (Baria et al, 2001). This indicates a subpopulation
of sensitive individuals who will be exceedingly sensitive to
radiation-induced cancers (Brenner et al, 2003). A study of cell
lines from prostate cancer cases found greater G2 chromosomal
radiosensitivity when compared with cell lines from healthy
controls (Howe et al, 2005).
Thus there is the possibility for gene-environment interactions
to take place in the case of exposures to low dose ionising
radiation. We explored this by carrying out a separate analysis
for a subgroup of our sample that had a family history of
cancer. We had considered a separate analysis for subjects with a
family history of prostate cancer per se but because of the
small numbers in this subset this was not viable. Our results
showed that even in the subset comprising subjects with a family
history of cancer, prostate cancer cases were more likely to be
exposed to hip/pelvic x-rays. Moreover, the exposure odds in this
subgroup of cases increased when compared with the exposure
odds obtained from the analysis of all subjects (irrespective of
family history). Previous reports of candidate gene analyses in
YOPC have shown a small proportion harbour mutations in DNA
repair genes such as BRCA2 and CHEK2 (Dong et al, 2003;
Edwards et al, 2003; Cybulski et al, 2004). There is evidence
of susceptibility to breast cancers induced by low dose ionising
radiation from diagnostic procedures such as chest x-rays in
the case of BRCA1/2 mutation carriers (Andrieu et al, 2006). It
could be extrapolated from these studies and our own results that
certain individuals may be genetically susceptible to prostate
cancers induced by exposure to low-dose ionising radiation
provided by diagnostic radiological procedures in the region of
the prostate gland.
Finally, it is worth noting that computed tomography (CT) is
now widely used in place of many radiographic examinations and
the dose to the prostate from a CT scan of the pelvic region can be
around 20mGy, which is comparable to the dose to the prostate
from a barium enema examination. The International Commission
on Radiological Protection (ICRP, 2007) lists the tissues or organs
known to be radiation-sensitive to cancer induction. Normalised
tissue weighting factors that identify the relative sensitivities of
these organs and tissues is used in the calculation of effective dose.
This list does not specifically identify a tissue-weighting factor for
the prostate gland. The weighting factor for the prostate is shared
between 13 remainder organs whose total weighting factor is 0.12.
The Commission’s 2007 update has reduced the judged value of the
tissue-weighting factor for the gonads based on estimates of
genetic risks from continuous low-dose rate exposures. One of the
implications of our study results is the need for a renewed
evaluation of the ICRP tissue-weighting factors to take into
account the possible higher relative sensitivity of the prostate
gland. Until more evidence is available, practitioners should adopt
a more cautious approach to diagnostic radiology procedures and
consider an increasing use of magnetic resonance imaging (MRI)
as opposed to CT and better shielding of the prostate during such
procedures. This is echoed in the recent ICRP recommendations
which emphasise that the reduction in the gonadal tissue weighting
factor does not justify allowing controllable gonadal exposures to
increase in magnitude (ICRP, 2007).
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